drugset / Trial / NCT00605059

Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00605059 ↗

Phase 1 Terminated 3 enrolled Institute for Neurodegenerative Disorders
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV94, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects To perform blood metabolite characterization of 123-I AV94 in healthy and AD subjects to determine the metabolic fate and nature of metabolites in assessment of 123-I AV94 as a single photon computed tomography (SPECT) brain imaging agent Evaluate the test/retest reproducibility of 123-I AV94 and SPECT in AD subjects and healthy controls

Timeline

Start
2007-08
Primary completion
2008-06
Completion
2008-06

Outcome

Outcome not reported

Stopped: “Scans showed no visual difference between affected subjects \& healthy volunteers”

Drugs

EvaluationDrugModalityDoseRoute
Subject 123-I AV94 Diagnostic / imaging agent — —

Indications